Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

STRUGGLING to keep up with her two young children and dreading her own reflection in the mirror, Emma Lasenby knew something ...

In a phase 1 study, the seven patients given the highest dose tested reduced their weight by 5.3% on average after just 28 days of daily dosing ... candidate is called retatrutide, and it acts ...

A starting dose can begin at £180 and then go up depending on increases in dosage. She said ... Containing the active ingredient retatrutide, slimmers trying the drug lost up to 29 per ...

Retatrutide targets GIP and GLP-1 – the same ... and type 2 diabetes will be finalised by the end of 2023. Twice-daily dosing would put danuglipron at a disadvantage to Lilly’s oral GLP ...

Looking ahead, the company is progressing with retatrutide in obesity and diabetes, lepodisiran for cardiovascular disease and a number of other compounds in immunology and oncology. Such a ...

The prescribed dosage for fluoxetine may depend on a person’s individual treatment plan. Other factors, including your specific diagnosis, body weight, and medical history, may affect your ...

To learn more about Azstarys, see this Azstarys overview. Your doctor likely will start your treatment with an Azstarys dosage of 39.2 mg/7.8 mg once per day. They may increase the dosage after 1 ...